LXRX Overview

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the research and development of pilavapadin, LX9851 and sotagliflozin and the commercialization of INPEFA. It is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. It has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. It is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. It is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.

Wall Street analysts forecast LXRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LXRX is4.03 USD with a low forecast of 2.10 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Lexicon Pharmaceuticals Inc revenue for the last quarter amounts to 5.49M USD, decreased -79.31

Lexicon Pharmaceuticals Inc. EPS for the last quarter amounts to -0.04 USD, decreased -55.56

Lexicon Pharmaceuticals Inc (LXRX) has 81 emplpoyees as of March 12 2026.

Today LXRX has the market capitalization of 728.73M USD.